| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Apixaban versus warfarin in patients with atrial fibrillation.
|
N Engl J Med
|
2011
|
23.50
|
|
2
|
Apixaban with antiplatelet therapy after acute coronary syndrome.
|
N Engl J Med
|
2011
|
4.81
|
|
3
|
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
|
Circulation
|
2013
|
3.25
|
|
4
|
Association between endoscopic vs open vein-graft harvesting and mortality, wound complications, and cardiovascular events in patients undergoing CABG surgery.
|
JAMA
|
2012
|
3.00
|
|
5
|
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.
|
Eur Heart J
|
2012
|
2.94
|
|
6
|
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
|
J Am Coll Cardiol
|
2013
|
2.90
|
|
7
|
International variation in and factors associated with hospital readmission after myocardial infarction.
|
JAMA
|
2012
|
2.75
|
|
8
|
Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial.
|
Circulation
|
2011
|
2.52
|
|
9
|
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial.
|
Eur Heart J
|
2013
|
2.27
|
|
10
|
Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials.
|
Circ Arrhythm Electrophysiol
|
2009
|
2.19
|
|
11
|
Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome.
|
Am Heart J
|
2013
|
2.14
|
|
12
|
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.
|
Lancet Neurol
|
2012
|
1.99
|
|
13
|
Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial.
|
JAMA
|
2012
|
1.87
|
|
14
|
Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention.
|
JAMA
|
2009
|
1.80
|
|
15
|
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF.
|
Am Heart J
|
2011
|
1.72
|
|
16
|
Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review.
|
Ann Intern Med
|
2014
|
1.67
|
|
17
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
|
Circulation
|
2012
|
1.66
|
|
18
|
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
|
Circulation
|
2013
|
1.63
|
|
19
|
Identifying patients at risk for premature discontinuation of thienopyridine after coronary stent implantation.
|
Am J Cardiol
|
2010
|
1.48
|
|
20
|
Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting.
|
J Thromb Thrombolysis
|
2013
|
1.48
|
|
21
|
New-onset atrial fibrillation after acute myocardial infarction and its relation to admission biomarkers (from the TRIUMPH registry).
|
Am J Cardiol
|
2013
|
1.43
|
|
22
|
Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomes.
|
Circ Cardiovasc Interv
|
2013
|
1.30
|
|
23
|
Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions.
|
Ann Surg
|
2013
|
1.25
|
|
24
|
Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
|
Am Heart J
|
2013
|
1.14
|
|
25
|
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy.
|
Int J Cardiol
|
2013
|
1.11
|
|
26
|
Results of a reevaluation of cardiovascular outcomes in the RECORD trial.
|
Am Heart J
|
2013
|
1.10
|
|
27
|
Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician.
|
J Thromb Thrombolysis
|
2011
|
1.08
|
|
28
|
Comment on: editorial by Husted et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 111: 781-782).
|
Thromb Haemost
|
2014
|
1.07
|
|
29
|
Age and outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: findings from the APEX-AMI trial.
|
Arch Intern Med
|
2011
|
1.06
|
|
30
|
New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs.
|
Thromb Haemost
|
2010
|
1.06
|
|
31
|
Impact of recovery of renal function on long-term mortality after coronary artery bypass grafting.
|
Am J Cardiol
|
2010
|
1.05
|
|
32
|
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
|
Eur Heart J
|
2013
|
1.03
|
|
33
|
High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
|
Circulation
|
2013
|
0.99
|
|
34
|
Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
|
Circ Cardiovasc Qual Outcomes
|
2013
|
0.97
|
|
35
|
Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights.
|
Circ Cardiovasc Qual Outcomes
|
2012
|
0.97
|
|
36
|
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
|
Circ Cardiovasc Qual Outcomes
|
2012
|
0.96
|
|
37
|
Regulation of inflammation in the adipose tissue in cancer cachexia: effect of exercise.
|
Cell Biochem Funct
|
2009
|
0.95
|
|
38
|
Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial.
|
Circ Heart Fail
|
2013
|
0.94
|
|
39
|
Red versus white thrombi in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: clinical and angiographic outcomes.
|
Am Heart J
|
2012
|
0.93
|
|
40
|
Surgical Maze procedure as a treatment for atrial fibrillation: a meta-analysis of randomized controlled trials.
|
Cardiovasc Ther
|
2010
|
0.91
|
|
41
|
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial.
|
J Thromb Thrombolysis
|
2012
|
0.90
|
|
42
|
Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.
|
J Thromb Thrombolysis
|
2012
|
0.88
|
|
43
|
Treatment of venous thromboembolism: guidelines translated for the clinician.
|
J Thromb Thrombolysis
|
2009
|
0.88
|
|
44
|
Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients.
|
JACC Cardiovasc Interv
|
2012
|
0.86
|
|
45
|
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
|
Curr Opin Cardiol
|
2010
|
0.86
|
|
46
|
Relationship of the time interval between cardiac catheterization and elective coronary artery bypass surgery with postprocedural acute kidney injury.
|
Circulation
|
2011
|
0.86
|
|
47
|
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction.
|
Am Heart J
|
2012
|
0.86
|
|
48
|
Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis.
|
Am J Cardiol
|
2011
|
0.85
|
|
49
|
Endoscopic harvesting device type and outcomes in patients undergoing coronary artery bypass surgery.
|
Ann Surg
|
2014
|
0.85
|
|
50
|
Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction.
|
J Am Coll Cardiol
|
2012
|
0.85
|
|
51
|
Program for the epidemiological evaluation of stroke in Tandil, Argentina (PREVISTA) study: rationale and design.
|
Int J Stroke
|
2013
|
0.85
|
|
52
|
Hospital length of stay in patients with non-ST-segment elevation myocardial infarction.
|
Am J Med
|
2012
|
0.84
|
|
53
|
Late-onset bloodstream infections in hospitalized term infants.
|
Pediatr Infect Dis J
|
2014
|
0.84
|
|
54
|
Natriuretic peptides and long-term mortality in patients with severe aortic stenosis.
|
J Heart Valve Dis
|
2012
|
0.83
|
|
55
|
Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy.
|
Am J Med
|
2011
|
0.82
|
|
56
|
Status quo of hybrid coronary revascularization for multi-vessel coronary artery disease.
|
Ann Thorac Surg
|
2013
|
0.82
|
|
57
|
Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis.
|
Intensive Care Med
|
2013
|
0.82
|
|
58
|
Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study.
|
Am Heart J
|
2013
|
0.81
|
|
59
|
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.
|
Am Heart J
|
2012
|
0.81
|
|
60
|
Are racial/ethnic gaps in the use of cardiac resynchronization therapy narrowing?: an analysis of 107,096 patients from the National Cardiovascular Data Registry's ICD Registry.
|
J Am Coll Cardiol
|
2012
|
0.81
|
|
61
|
International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation.
|
Am Heart J
|
2012
|
0.81
|
|
62
|
Do omega-3 fatty acids prevent atrial fibrillation after open heart surgery? A meta-analysis of randomized controlled trials.
|
Clinics (Sao Paulo)
|
2011
|
0.80
|
|
63
|
Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY.
|
Am Heart J
|
2010
|
0.80
|
|
64
|
Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy.
|
Am Heart J
|
2013
|
0.80
|
|
65
|
Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial.
|
Am J Med
|
2011
|
0.79
|
|
66
|
Saphenous vein graft failure and clinical outcomes: toward a surrogate end point in patients following coronary artery bypass surgery?
|
Am Heart J
|
2013
|
0.79
|
|
67
|
Cardiovascular clinical research in South America.
|
Am Heart J
|
2013
|
0.79
|
|
68
|
The usefulness of T-wave peak to T-wave end interval in identifying malignant arrhythmias in patients with Chagas disease.
|
Hellenic J Cardiol
|
2013
|
0.78
|
|
69
|
Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial.
|
Int J Cardiol
|
2013
|
0.78
|
|
70
|
Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease?
|
Am Heart J
|
2010
|
0.78
|
|
71
|
Perioperative management of anticoagulation: guidelines translated for the clinician.
|
J Thromb Thrombolysis
|
2009
|
0.78
|
|
72
|
Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry.
|
Circulation
|
2012
|
0.78
|
|
73
|
Antithrombotic therapy for ischemic stroke: guidelines translated for the clinician.
|
J Thromb Thrombolysis
|
2010
|
0.77
|
|
74
|
Cardiopulmonary exercise and 6-min walk tests as predictors of quality of life and long-term mortality among patients with heart failure due to Chagas disease.
|
Int J Cardiol
|
2013
|
0.77
|
|
75
|
Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial.
|
J Electrocardiol
|
2010
|
0.77
|
|
76
|
Endothelial function in patients with slow coronary flow and normal coronary angiography.
|
Clinics (Sao Paulo)
|
2012
|
0.77
|
|
77
|
Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation.
|
J Thromb Thrombolysis
|
2014
|
0.76
|
|
78
|
Endurance training modulates lymphocyte function in rats with post-MI CHF.
|
Med Sci Sports Exerc
|
2008
|
0.76
|
|
79
|
Inflammation and circulating endothelial progenitor cells in patients with coronary artery disease and residual platelet reactivity.
|
Clinics (Sao Paulo)
|
2012
|
0.76
|
|
80
|
The reply.
|
Am J Med
|
2013
|
0.75
|
|
81
|
Serious infection after acute myocardial infarction: incidence, clinical features, and outcomes.
|
JACC Cardiovasc Interv
|
2012
|
0.75
|
|
82
|
Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation".
|
Circulation
|
2014
|
0.75
|
|
83
|
Responding to the letter to the editor by Saver.
|
Am Heart J
|
2013
|
0.75
|
|
84
|
Coronary embolism and calcified aortic valve: is there a correlation?
|
J Thromb Thrombolysis
|
2012
|
0.75
|
|
85
|
Highlights from American Heart Association, November 4-7, 2007, Orlando, Florida, USA. Late-breaking trials summary.
|
Am Heart J
|
2008
|
0.75
|
|
86
|
Heart failure survival score in patients with Chagas disease: correlation with functional variables.
|
Rev Esp Cardiol (Engl Ed)
|
2012
|
0.75
|
|
87
|
Promise of factor Xa inhibition in atrial fibrillation.
|
Curr Cardiol Rep
|
2012
|
0.75
|
|
88
|
Anger control and cardiovascular outcomes.
|
Int J Cardiol
|
2013
|
0.75
|
|
89
|
Relationship of sustained ventricular tachyarrhythmias to outcomes in patients undergoing primary percutaneous coronary intervention with varying underlying baseline risk.
|
Am Heart J
|
2011
|
0.75
|
|
90
|
Prophylaxis for venous thromboembolism: guidelines translated for the clinician.
|
J Thromb Thrombolysis
|
2011
|
0.75
|
|
91
|
Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia.
|
Curr Cardiol Rep
|
2007
|
0.75
|
|
92
|
Gastroesophageal reflux and atrial fibrillation: is there any correlation?
|
Expert Rev Cardiovasc Ther
|
2012
|
0.75
|
|
93
|
Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials.
|
EuroIntervention
|
2017
|
0.75
|
|
94
|
Mortality after myocardial infarction: the role of renal function and systolic and diastolic functions of the left ventricle.
|
J Nephrol
|
2013
|
0.75
|
|
95
|
Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes.
|
J Am Coll Cardiol
|
2013
|
0.75
|
|
96
|
A multifaceted intervention to narrow the evidence-based gap in the treatment of acute coronary syndromes: rationale and design of the Brazilian Intervention to Increase Evidence Usage in Acute Coronary Syndromes (BRIDGE-ACS) cluster-randomized trial.
|
Am Heart J
|
2012
|
0.75
|
|
97
|
Highlights from the 56th annual scientific sessions of the American College of Cardiology: March 25 to 27, 2007, Atlanta, Georgia.
|
Am Heart J
|
2007
|
0.75
|
|
98
|
Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician.
|
J Thromb Thrombolysis
|
2010
|
0.75
|
|
99
|
Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
|
Crit Care Med
|
2014
|
0.75
|
|
100
|
The safety and efficacy of apixaban : where do we stand in 2013?
|
Expert Opin Drug Saf
|
2013
|
0.75
|
|
101
|
Prehospitalization antiplatelet therapy and outcomes after saphenous vein graft intervention.
|
Am J Cardiol
|
2012
|
0.75
|
|
102
|
Interpreting the TRITON results in light of the event adjudication process.
|
Cardiology
|
2009
|
0.75
|
|
103
|
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
|
Postgrad Med
|
2013
|
0.75
|
|
104
|
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial.
|
Coron Artery Dis
|
2013
|
0.75
|
|
105
|
Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial.
|
Am Heart J
|
2012
|
0.75
|